Published in N Engl J Med on October 26, 2006
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism | NCT00264277
DULCIS (D-dimer and ULtrasonography in Combination Italian Study) (DULCIS) | NCT00954395
Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis | NCT00437892
The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol (2008) 3.50
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26
Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ (2014) 2.80
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Epidemiology and risk factors for venous thrombosis. Semin Hematol (2007) 1.90
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62
Risk factors for venous and arterial thrombosis. Blood Transfus (2010) 1.58
Resolution of left atrial appendage thrombus with apixaban. Thromb J (2013) 1.35
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Clinical update on pulmonary embolism. Arch Med Sci (2013) 0.96
Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96
D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc (2014) 0.91
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86
Diagnosis of deep vein thrombosis, and prevention of deep vein thrombosis recurrence and the post-thrombotic syndrome in the primary care medicine setting anno 2014. World J Crit Care Med (2015) 0.86
Optimal duration of anticoagulation after venous thromboembolism. Circulation (2011) 0.85
Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord (2007) 0.83
Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review. Biomark Insights (2008) 0.83
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82
Surveying the medical literature: five notable articles in general internal medicine from 2008 and 2009. Open Med (2010) 0.82
Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One (2014) 0.80
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.79
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Medical management of venous thromboembolism: what the interventional radiologist needs to know. Semin Intervent Radiol (2012) 0.78
Recent advances in the management of venous thromboembolism. Korean J Hematol (2010) 0.78
Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78
Epidemiology of recurrent venous thrombosis. Braz J Med Biol Res (2011) 0.78
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Elevation in D-dimer concentrations is positively correlated with gestation in normal uncomplicated pregnancy. Int J Womens Health (2012) 0.77
D-dimer and duration of anticoagulation. N Engl J Med (2007) 0.77
Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis (2008) 0.77
Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study. PLoS One (2016) 0.77
Long-term prognosis and related factors towards patients with acute pulmonary thromboembolism. Int J Clin Exp Med (2015) 0.77
Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke. J Oncol (2015) 0.77
Acute deep vein thrombosis cases in the real world. Semin Intervent Radiol (2012) 0.76
Association between D-dimer level and portal venous system thrombosis in liver cirrhosis: a retrospective observational study. Int J Clin Exp Med (2015) 0.76
D-dimer level for predicting the in-hospital mortality in liver cirrhosis: A retrospective study. Exp Ther Med (2016) 0.75
Update in general internal medicine. J Gen Intern Med (2009) 0.75
D-dimer and duration of anticoagulation. N Engl J Med (2007) 0.75
D-dimer and duration of anticoagulation. N Engl J Med (2007) 0.75
Optimal duration of anticoagulation in patients with venous thromboembolism. Indian J Med Res (2011) 0.75
Stopping anticoagulant therapy after an unprovoked venous thromboembolism. CMAJ (2008) 0.75
The role of soluble fibrin during anticoagulant therapy: a case report. Thromb J (2015) 0.75
[Optimal time to introduce secondary prophylactic anticoagulation therapy after an episode of obstructive lung disease or venous thrombosis - will it be defined by testing of D-dimer?]. Kardiol Pol (2007) 0.75
An abnormal D-dimer test result indicated that anticoagulation should be continued. ACP J Club (2007) 0.75
Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism. Mol Med Rep (2015) 0.75
Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study. PLoS One (2016) 0.75
Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women. Haematologica (2010) 0.75
Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis (2010) 0.75
Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism. PLoS One (2016) 0.75
An Intact Dissecting Baker's Cyst Mimicking Recurrent Deep Vein Thrombosis. J Investig Med High Impact Case Rep (2016) 0.75
The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75
An abnormal D-dimer test result indicated that anticoagulant therapy should be continued. Evid Based Med (2007) 0.75
Assessing the risk of recurrent venous thromboembolism--a practical approach. Vasc Health Risk Manag (2015) 0.75
Managing pulmonary embolism using prognostic models: future concepts for primary care. CMAJ (2011) 0.75
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. Vasc Specialist Int (2016) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
D-dimer and duration of anticoagulation. N Engl J Med (2007) 0.75
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Interventions for enhancing medication adherence. Cochrane Database Syst Rev (2014) 2.82
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med (2013) 2.64
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation (2011) 2.60
Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost (2002) 2.44
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Applicability of the AGREE II instrument in evaluating the development process and quality of current National Academy of Clinical Biochemistry guidelines. Clin Chem (2012) 2.21
Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation (2010) 2.12
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol (2006) 2.09
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther (2002) 2.08
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol (2012) 2.07
Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn (2015) 2.06
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol (2005) 1.99
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. Ann Intern Med (2002) 1.86
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med (2010) 1.83
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood (2011) 1.79
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2011) 1.78
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica (2004) 1.73
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res (2009) 1.72
Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol (2005) 1.67
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med (2003) 1.52
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol (2015) 1.48
Low-dose heparin for severe sepsis. N Engl J Med (2002) 1.47
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis (2007) 1.47
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost (2009) 1.46
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost (2012) 1.45
A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med (2014) 1.45
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. Ann Intern Med (2014) 1.42
In-vitro detection of thrombotic formation on bileaflet mechanical heart valves. J Heart Valve Dis (2011) 1.40
Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem (2006) 1.40
Diagnosis of deep vein thrombosis. Semin Thromb Hemost (2006) 1.39
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood (2013) 1.39
Repeated graft loss caused by recurrent hepatic artery thrombosis after liver transplantation. Liver Transpl (2003) 1.38
Interventional approach to reduce thromboembolic risk in patients with atrial fibrillation ineligible for oral anticoagulation. Ital Heart J (2005) 1.38
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost (2009) 1.34
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood (2008) 1.30
Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. Am J Public Health (2014) 1.30
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med (2010) 1.27
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost (2015) 1.20
Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med (2013) 1.19
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics (2011) 1.14
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation (2003) 1.13
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood (2007) 1.13
Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events. Stroke (2008) 1.11
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol (2005) 1.09
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost (2013) 1.07
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) (2011) 1.06
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost (2015) 1.06
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood (2012) 1.05
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood (2009) 1.02
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin (2014) 1.01
Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica (2012) 1.00
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost (2012) 0.99